Cat. No.: DPP-001096
Product Overview | |
---|---|
Species | Human |
Expression System | HEK 293 cells |
Endotoxin Level | < 1.000 Eu/µg |
Format | Lyophilized |
Purity | ≥97% by SDS-PAGE |
Nature | Recombinant |
Target Information | |
---|---|
Gene Name | ENPP1 |
UniProt No. | P22413 |
Gene ID | 5167 |
Molecular Weight | 97 kDa including tags |
Alternative Names | Alkaline phosphodiesterase 1; ARHR2; COLED; E-NPP 1; Ectonucleotide pyrophosphatase/phosphodiesterase 1; Ectonucleotide pyrophosphatase/phosphodiesterase family member 1; ENPP1; ENPP1_HUMAN; Ly 41 antigen; M6S1; Membrane component chromosome 6 surface marker 1; NPP1; NPPase; NPPS; Nucleotide pyrophosphatase; PC 1; PC-1; PCA1; PDNP1; Phosphodiesterase I/nucleotide pyrophosphatase 1; Plasma cell membrane glycoprotein 1; Plasma-cell membrane glycoprotein PC-1 |
Function | Involved primarily in ATP hydrolysis at the plasma membrane. Plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. In vitro, has a broad specificity, hydrolyzing other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP. May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling. Appears to modulate insulin sensitivity. |
Involvement In Disease | Defects in ENPP1 are a cause of increased susceptibility for ossification of the posterior longitudinal ligament of the spine (OPLL). OPLL is a common form of human myelopathy with a prevalence of as much as 4% in a variety of ethnic groups.Defects in ENPP1 are the cause of arterial calcification of infancy, generalized, type 1 (GACI1). A severe autosomal recessive disorder characterized by calcification of the internal elastic lamina of muscular arteries and stenosis due to myointimal proliferation. The disorder is often fatal within the first 6 months of life because of myocardial ischemia resulting in refractory heart failure.Defects in ENPP1 are associated with obesity, glucose intolerance, and type II diabetes non-insulin dependent (NIDDM) .Defects in ENPP1 are the cause of rickets hypophosphatemic autosomal recessive type 2 (ARHR2). ARHR2 is a hereditary form of hypophosphatemic rickets, a disorder of proximal renal tubule function that causes phosphate loss, hypophosphatemia and skeletal deformities, including rickets and osteomalacia unresponsive to vitamin D. Symptoms are bone pain, fractures and growth abnormalities. |
Cellular Localization | Membrane. Basolateral cell membrane. Targeted to the basolateral membrane in polarized epithelial cells and in hepatocytes, and to matrix vesicles in osteoblasts. In bile duct cells and cancer cells, located to the apical cytoplasmic side. |
Protein Length | Protein fragment |
Sequence | ASKPSCAKEV KSCKGRCFER TFGNCRCDAA CVELGNCCLD YQETCIEPEH IWTCNKFRCG EKRLTRSLCA CSDDCKDKGD CCINYSSVCQ GEKSWVEEPC ESINEPQCPA GFETPPTLLF SLDGFRAEYL HTWGGLLPVI SKLKKCGTYT KNMRPVYPTK TFPNHYSIVT GLYPESHGII DNKMYDPKMN ASFSLKSKEK FNPEWYKGEP IWVTAKYQGL KSGTFFWPGS DVEINGIFPD IYKMYNGSVP FEERILAVLQ WLQLPKDERP HFYTLYLEEP DSSGHSYGPV SSEVIKALQR VDGMVGMLMD GLKELNLHRC LNLILISDHG MEQGSCKKYI YLNKYLGDVK NIKVIYGPAA RLRPSDVPDK YYSFNYEGIA RNLSCREPNQ HFKPYLKHFL PKRLHFAKSD RIEPLTFYLD PQWQLALNPS ERKYCGSGFH GSDNVFSNMQ ALFVGYGPGF KHGIEADTFE NIEVYNLMCD LLNLTPAPNN GTHGSLNHLL KNPVYTPKHP KEVHPLVQCP FTRNPRDNLG CSCNPSILPI EDFQTQFNLT VAEEKIIKHE TLPYGRPRVL QKENTICLLS QHQFMSGYSQ DILMPLWTSY TVDRNDSFST EDFSNCLYQD FRIPLSPVHK CSFYKNNTKV SYGFLSPPQL NKNSSGIYSE ALLTTNIVPM YQSFQVIWRY FHDTLLRKYA EERNGVNVVS GPVFDFDYDG RCDSLENLRQ KRRVIRNQEI LIPTHFFIVL TSCKDTSQTP LHCENLDTLA FILPHRTDNS ESCVHGKHDS SWVEELLMLH RARITDVEHI TGLSFYQQRK EPVSDILKLK THLPTFSQED GPKLHHHHHH,Belongs to the nucleotide pyrophosphatase/phosphodiesterase family. Contains 2 SMB (somatomedin-B) domains. |
Shipping & Storage | |
---|---|
Shipping | Shipped on dry ice. |
Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.